Year Founded
2014
Ownership
Private
Employees
~10
Therapeutic Areas
Pulmonology
Stage
Phase 2
Modalities
Small molecule

Enterprise Therapeutics General Information

Lead program ETD001 is in Phase 2a clinical trial for cystic fibrosis. ETD001 is a novel ENaC blocker designed to be long-acting with durable target engagement.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Brighton,
United Kingdom

Drug Pipeline

ETD001
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Enterprise Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Enterprise Therapeutics Funding

Deal TypeDateAmountStatusStage
Later Stage VCJan 29, 2024$33.1MCompletedPhase 2
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Enterprise Therapeutics's complete valuation and funding history, request access »

Enterprise Therapeutics Investors

Novartis Venture Fund
Investor Type: Venture Capital
Holding: Minority
Versant Ventures
Investor Type: Venture Capital
Holding: Minority
Forbion
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 5 investors. Get the full list »